214 related articles for article (PubMed ID: 18473764)
1. Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer.
Atreya R; Neurath MF
Curr Drug Targets; 2008 May; 9(5):369-74. PubMed ID: 18473764
[TBL] [Abstract][Full Text] [Related]
2. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development.
Waldner MJ; Neurath MF
Semin Immunol; 2014 Feb; 26(1):75-9. PubMed ID: 24447345
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Rose-John S; Mitsuyama K; Matsumoto S; Thaiss WM; Scheller J
Curr Pharm Des; 2009; 15(18):2095-103. PubMed ID: 19519447
[TBL] [Abstract][Full Text] [Related]
4. Dietary cocoa inhibits colitis associated cancer: a crucial involvement of the IL-6/STAT3 pathway.
Saadatdoust Z; Pandurangan AK; Ananda Sadagopan SK; Mohd Esa N; Ismail A; Mustafa MR
J Nutr Biochem; 2015 Dec; 26(12):1547-58. PubMed ID: 26355019
[TBL] [Abstract][Full Text] [Related]
5. Oroxylin A inhibits colitis-associated carcinogenesis through modulating the IL-6/STAT3 signaling pathway.
Yang X; Zhang F; Wang Y; Cai M; Wang Q; Guo Q; Li Z; Hu R
Inflamm Bowel Dis; 2013 Aug; 19(9):1990-2000. PubMed ID: 23823704
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of IL6/IL6R-STAT3-SOCS3 signaling pathway in IBD-associated colorectal dysplastic lesions as compared to sporadic colorectal adenomas in non-IBD patients.
Gui X; Iacucci M; Ghosh S
Pathol Res Pract; 2020 Nov; 216(11):153211. PubMed ID: 32979687
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.
Mitsuyama K; Matsumoto S; Masuda J; Yamasakii H; Kuwaki K; Takedatsu H; Sata M
Anticancer Res; 2007; 27(6A):3749-56. PubMed ID: 17970038
[TBL] [Abstract][Full Text] [Related]
8. Chemopreventive Effects of Silibinin on Colitis-Associated Tumorigenesis by Inhibiting IL-6/STAT3 Signaling Pathway.
Zheng R; Ma J; Wang D; Dong W; Wang S; Liu T; Xie R; Liu L; Wang B; Cao H
Mediators Inflamm; 2018; 2018():1562010. PubMed ID: 30498394
[TBL] [Abstract][Full Text] [Related]
9. The Role of Proinflammatory Pathways in the Pathogenesis of Colitis-Associated Colorectal Cancer.
Luo C; Zhang H
Mediators Inflamm; 2017; 2017():5126048. PubMed ID: 28852270
[TBL] [Abstract][Full Text] [Related]
10. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases.
Mudter J; Weigmann B; Bartsch B; Kiesslich R; Strand D; Galle PR; Lehr HA; Schmidt J; Neurath MF
Am J Gastroenterol; 2005 Jan; 100(1):64-72. PubMed ID: 15654782
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic targets for inflammatory bowel disease.
Argollo M; Fiorino G; Hindryckx P; Peyrin-Biroulet L; Danese S
J Autoimmun; 2017 Dec; 85():103-116. PubMed ID: 28711286
[TBL] [Abstract][Full Text] [Related]
12. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
13. IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid.
Rafa H; Saoula H; Belkhelfa M; Medjeber O; Soufli I; Toumi R; de Launoit Y; Moralès O; Nakmouche M; Delhem N; Touil-Boukoffa C
J Interferon Cytokine Res; 2013 Jul; 33(7):355-68. PubMed ID: 23472658
[TBL] [Abstract][Full Text] [Related]
14. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis.
Li Y; de Haar C; Chen M; Deuring J; Gerrits MM; Smits R; Xia B; Kuipers EJ; van der Woude CJ
Gut; 2010 Feb; 59(2):227-35. PubMed ID: 19926618
[TBL] [Abstract][Full Text] [Related]
15. PDCD4 Deficiency Aggravated Colitis and Colitis-associated Colorectal Cancer Via Promoting IL-6/STAT3 Pathway in Mice.
Wang L; Zhao M; Guo C; Wang G; Zhu F; Wang J; Wang X; Wang Q; Zhao W; Shi Y; Chen YH; Zhang L
Inflamm Bowel Dis; 2016 May; 22(5):1107-18. PubMed ID: 26891257
[TBL] [Abstract][Full Text] [Related]
16. Effects of growth arrest and DNA damage-inducible protein 34 (GADD34) on inflammation-induced colon cancer in mice.
Tanaka Y; Ito S; Oshino R; Chen N; Nishio N; Isobe K
Br J Cancer; 2015 Aug; 113(4):669-79. PubMed ID: 26196182
[TBL] [Abstract][Full Text] [Related]
17. Emerging Roles for Noncanonical NF-κB Signaling in the Modulation of Inflammatory Bowel Disease Pathobiology.
McDaniel DK; Eden K; Ringel VM; Allen IC
Inflamm Bowel Dis; 2016 Sep; 22(9):2265-79. PubMed ID: 27508514
[TBL] [Abstract][Full Text] [Related]
18. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M; Salem M; Pedersen J; Nielsen OH
Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
[TBL] [Abstract][Full Text] [Related]
19. The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6.
Vetrano S; Borroni EM; Sarukhan A; Savino B; Bonecchi R; Correale C; Arena V; Fantini M; Roncalli M; Malesci A; Mantovani A; Locati M; Danese S
Gut; 2010 Feb; 59(2):197-206. PubMed ID: 19846409
[TBL] [Abstract][Full Text] [Related]
20. Stat3: friend or foe in colitis and colitis-associated cancer?
Han J; Theiss AL
Inflamm Bowel Dis; 2014 Dec; 20(12):2405-11. PubMed ID: 25185686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
